CanBas Co., Ltd. (JP:4575)

:4575

4575

CanBas Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4575 full AI Analyst Report?

CanBas Co., Ltd. (4575) Price & Analysis

0 Followers

4575 Stock Chart & Stats

¥787.00

-¥23.00(-2.48%)

At close: Jan 08 4:00 PM EST

¥787.00

-¥23.00(-2.48%)

Day’s Range― - ―

52-Week Range¥643.00 - ¥1,558.00

Previous CloseN/A

Volume347.00K

Average Volume (3M)268.48K

Market Cap

¥13.11B

Enterprise Value¥11.34B

Total Cash (Recent Filing)¥2.83B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-61.17

Shares Outstanding19,713,655

10 Day Avg. Volume208,910

30 Day Avg. Volume268,476

Financial Highlights & Ratios

PEG Ratio1.96

Price to Book (P/B)7.69

Price to Sales (P/S)0.00

P/FCF Ratio-29.34

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

De-risked Balance SheetZero reported debt and a meaningful equity increase materially reduce leverage risk and improve solvency. This stronger capitalization lengthens runway and improves negotiating leverage with partners and financiers, lowering the probability of distress while the company pursues clinical milestones.

Licensing And Collaboration ModelA business model centered on licensing and collaborations aligns incentives with larger partners and can generate milestone and royalty streams without sole commercialization burden. Structurally this approach can scale value per successful asset while sharing development risk and providing potential non-dilutive or milestone-driven cash inflows.

Improving Cash Burn TrendA noticeable reduction in annual cash burn indicates management has begun slowing negative cash flow, extending runway. Sustained improvement can reduce reliance on frequent financing, improve strategic optionality for licensing deals, and demonstrate operational discipline in allocating scarce R&D resources.

Bears Say

Persistent Operating LossesConsistent operating and net losses reflect a pre-commercial biotech profile where R&D outlays exceed any product revenue. Over the medium term this keeps profitability out of reach absent successful collaborations or approvals and makes shareholder returns contingent on binary clinical and licensing outcomes.

Ongoing Negative Cash FlowPersistent negative operating and free cash flow forces repeated external financing or dilutive deals to fund R&D. That dependency raises execution risk, can dilute existing shareholders, and leaves long-term planning vulnerable to capital market conditions and the timing of milestone receipts.

Low Revenue Visibility & Weak ReturnsNear-zero revenue and deeply negative ROE signal limited current commercial traction and value erosion of shareholder capital. Without clearer revenue streams or successful out-licensing events, long-term cash generation and return prospects remain highly uncertain and dependent on binary development successes.

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?

CanBas Co., Ltd. lowest stock price was ¥643.00 and its highest was ¥1558.00 in the past 12 months.

What is CanBas Co., Ltd.’s market cap?

CanBas Co., Ltd.’s market cap is ¥13.11B.

When is CanBas Co., Ltd.’s upcoming earnings report date?

CanBas Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 83 days.

How were CanBas Co., Ltd.’s earnings last quarter?

CanBas Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥15.48 earnings per share for the quarter, missing the consensus estimate of N/A by -¥15.48.

Is CanBas Co., Ltd. overvalued?

According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CanBas Co., Ltd. pay dividends?

CanBas Co., Ltd. does not currently pay dividends.

What is CanBas Co., Ltd.’s EPS estimate?

CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CanBas Co., Ltd. have?

CanBas Co., Ltd. has 19,713,655 shares outstanding.

What happened to CanBas Co., Ltd.’s price movement after its last earnings report?

CanBas Co., Ltd. reported an EPS of -¥15.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.

Which hedge fund is a major shareholder of CanBas Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4575

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CanBas Co., Ltd.

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.